Follow Us:
Wednesday, July 06, 2022

Gilead Sciences


Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

July 30, 2021 9:35 am

Sales of HIV medicines, which have stalled during the coronavirus pandemic, fell 2 per cent to $3.9 billion.

Gilead announces steps to expand availability of remdesivir in India

April 27, 2021 10:11 am

In addition to providing support to its licensees to expand their local manufacturing capacity, Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients, the company said.

Explained: Why WHO vs Gilead on Remdesivir matters

October 19, 2020 12:53 pm

What do the WHO Solidarity trial data say about the effectiveness of remdesivir? What is the drugmaker’s retort, and what does this mean for the treatment line for Covid-19?

Gilead Sciences announces approval of Remdesivir in India for patients with severe Covid-19

June 04, 2020 12:25 am

A statement issued on Wednesday stated that the regulatory approval is supported by clinical data from the US National Institute of Allergy and Infectious Diseases’

US pharma giant Gilead Sciences seeks marketing authorisation from India for remdesivir

May 30, 2020 11:17 am

Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said. The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised coronavirus patients.

Gilead says remdesivir shows improvement in COVID-19 patients when used early

April 29, 2020 10:11 pm

Interest in Gilead’s drug has been high as there are currently no approved treatments or preventive vaccines for COVID-19, and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in extremely severe cases.

Gilead to license hepatitis C drug to Indian firms

April 09, 2014 1:39 am

Gilead is under pressure to address the high cost of its breakthrough pill, which is the first of a new wave of drugs that have been shown to raise cure rates and cut treatment duration without the side effects.

CCI rules out case against US-based pharmaceutical,Gilead Sciences

March 12, 2013 2:53 pm

Fair trade regulator Competition Commission of India has rejected a complaint against Gilead Sciences Inc.

'MNCs ganged-up against Indian pharma'

March 07, 2011 3:08 pm

Global success in generics by Indian companies has created fear among MNCs.